Dual treatment with anti-CTLA-4 plus anti-PD-1 or anti-PD-L1 agents resulted in enhanced anti-tumor activity at the expense of increased toxicity for patients with some tumor types such as melanoma [107], but was unsuccessful in PDAC patients [24]. The gene discussed is CTLA4; the disease is melanoma.